Knockdown of CDKN2A using siRNA technology resulted in a significant decrease in Zeb1, vimentin, and MMP9, indicators related to BC cell migration and metastasis, as well as down-regulation of the expression of MEGEA4, phosphorylated STAT3, PD-L1, and caspase-3. The gene discussed is CDKN2A; the disease is breast cancer.